AIM ImmunoTech (AIM) announced updated terms for its previously announced rights offering. Each subscription right now entitles holders to purchase one unit, each Unit consisting of one share of the Company’s Series G Convertible Preferred Stock, and 2,000 Class G Common Stock Purchase Warrants to purchase the Company’s Common Stock at a subscription price of $1,000 per Unit. Each share of Preferred Stock will be convertible, at the option of the holder at any time, into 1,000 shares of Common Stock, which is equal to the quotient of the stated value of the Preferred Stock divided by the conversion price. Each Warrant will be exercisable for one share of Common Stock at an exercise price of $1.00 per share from the date of issuance through its expiration five years from the date of issuance. All record holders of rights certificates that wish to participate in the rights offering must deliver a properly completed and signed rights certificate, together with payment of the subscription price for both basic subscription rights and any over-subscription privilege election, to the Subscription Agent, to be received before 5:00 p.m. Eastern Time on March 3, 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AIM:
- AIM ImmunoTech extends subscription period of rights offering
- AIM announces planned milestones in Phase 2 trial of Ampligen, Durvalumab
- AIM ImmunoTech announces commencement of rights offering
- Biotech Alert: Searches spiking for these stocks today
- Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!
